09:15 AM EST, 11/19/2025 (MT Newswires) -- Health care stocks were mixed pre-bell Wednesday, with the Health Care Select Sector SPDR Fund ( XLV ) 0.1% lower and the iShares Biotechnology ETF (IBB) up 0.2%.

Agios Pharmaceuticals ( AGIO ) shares were down more than 49% after the company said its potential sickle cell disease treatment mitapivat failed to meet one of two primary endpoints in a 52-week phase 3 clinical trial.

EyePoint Pharmaceuticals ( EYPT ) stock was up more than 1% after the company said an independent Data Safety Monitoring Committee has recommended its ongoing pivotal phase 3 program evaluating Duravyu for the treatment of wet age-related macular degeneration continue as planned without any modifications to the protocol.

Viking Therapeutics ( VKTX ) shares were up nearly 2% after the company said it finished enrolling patients in its phase 3 Vanquish 1 study of a once-weekly subcutaneous drug for adults with obesity.